Irfan A. Asangani, Ph.D.

Assistant Professor, Department of Cancer Biology
Investigator, Abramson Family Cancer Research Institute
Core Member, Penn Epigenetics Institute
Perelman School of Medicine, University of Pennsylvania
Office: 611 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160
Phone: Office (215)746-8780; Lab (215)746-8781
Fax: (215)573-6725
Email: asangani@upenn.edu

APPOINTMENTS

2015-Oct-Present	Assistant Professor, Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
September 2015	Research Assistant Professor, Department of Pathology, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI.
2013-Aug. 2015	Research Investigator, Department of Pathology, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI.
2009-2012	Post-Doctoral Research Fellow, Michigan Center for Translational Pathology (MCTP), University of Michigan, Ann Arbor, MI.
2002-2004	Project Assistant, Department of Biochemistry/MCBL/MRDG, Indian Institute of Science, Bangalore, India.

ACADEMIC PROFILE

2004-2009	PhD, *Summa cum laude*, Klinikum Mannheim/ DKFZ / Heidelberg University, Germany.
1999-2001	Master of Science (Biochemistry), *First Class*, Madras University, India.
1996-1999	Bachelor of Science (Biochemistry), *First Class*, Madras University, India.

HONORS AND AWARDS

1. Conquer Cancer Now Award – Concern Foundation - 2020
2. Abramson Family Cancer Research Institute (AFCRI) Pilot Award for new Investigators – 2017.
3. Breakthrough Bike Challenge – Cooper Scholar Award – 2017.
4. K99/R00 NIH Pathway to Independence Award -2014
5. Best poster award in the 7th Annual Prostate Cancer Program Retreat. Fort Lauderdale, Florida. March 2014.
6. PCF (Prostate Cancer Foundation) Young Investigator Award -2013. 6. PCF (Prostate Cancer Foundation) Challenge Award -2013

7. AACR-Millennium Scholar-In-Training Award -2013.
8. Best poster award in the 5th Annual Prostate Cancer Program Retreat. Fort Lauderdale, Florida. March 2012.
9. DAAD travel grant to attend the DKFZ Alumni meeting 2010 in Heidelberg, Germany. June 2010.
10. Best poster award in 5th Colmar Scientific Symposium "the new RNA frontiers", Colmar, France. November 2007.
11. Invited as Young Researcher at the Lindau Nobel Laureate Meeting. Germany. June 2007.
12. Invited by Berlin-Summer School-2007 to represent DKFZ graduate students. Germany. April 2007.
13. Best participant award. miRNA workshop conducted by Ambion/Applied biosystems/EMBL at EMBL, Heidelberg, Germany. August 2006.

PATENTS

1. COMPOSITION AND METHODS FOR INHIBITING MMSET. Date of Patent 04.15.2014.U.S. Patent No.: US 8,697,407 B2 (Co-inventor)
2. 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors. USA Patent Number 10253044, 2019. (Co-inventor)
3. BET bromodomain inhibitors and therapeutic methods using the same. USA Patent Number 10391175, 2019. (Co-inventor)
4. TREATMENT OF CANCER WITH CDK INHIBITORS. Provisional Patent Filed 4.24.2019. Serial # serial number 62/838,271 (Senior-inventor)

ONGOING RESEARCH SUPPORT

PI: Asangani 04/01/2020-04/01/2025
Sponsor: NIH-NCI-US R01 Award – Role of MED1 in AR dependent transcription in advanced Prostate Cancer

PI: Asangani 08/01/2020-07/31/2022
Sponsor: AstraZeneca (SRA) –Role of NSD2 in mediating AR signaling in advanced prostate cancer

PI: Asangani 10/01/2020- 09/31/2022
Sponsor: Concern Foundation. Towards understanding and targeting transcriptional addiction in advanced prostate cancer.

PI: Asangani 07/01/2020- 06/31/2021
Sponsor: Sarcoma Foundation of America. EWS-FLI1 triggered opportunistic de novo enhancer assembly activates potential cellular therapy targets in Ewing Sarcoma

COMPLETED RESEARCH SUPPORT

PI: Asangani 08/01/2017- 07/31/2020
Sponsor: Department of Defense – Idea Development Award (W81XWH-17-1-0404)

PI: Asangani 04/01/2017-03/31/2019
Sponsor: Zenith Epigenetics (Scientific Research Agreement)

PI: Asangani 10/01/2015- 09/31/2018
Sponsor: R00 award. NIH-NCI-US (1K99CA187664-01)

PI: Asangani 11/01/2017- 05/30/2018
Sponsor: Abramson Family Cancer Research Institute – Pilot Award

PI: Asangani 01/01/2017- 12/31/2017
Sponsor: Breakthrough Bike Challenge – Cooper Scholar Award

PI: Asangani 01/01/2017- 12/31/2017
Sponsor: Epigenetics Institute, University of Pennsylvania

PI: Asangani 06/01/2013 – 05/30/2016
Sponsor: Prostate Cancer Foundation Young Investigator Award (2013-2016).

PI: Asangani 08/01/2014- 09/31/2015
Sponsor: K99 award. NIH-NCI-US (1K99CA187664-01)
Characterization of epigenetic targets in prostate cancer.

PUBLICATIONS (**Articles # 50, Google Scholar: Citations # 9,600, h-index # 32**)

2016 onwards (Independent phase)

1. **Asangani I.A.,** Blair I.A., Van Duyne G.D., Hilser V.J., Moiseenkova-Bell V.Y., Plymate S.R., Sprenger C.C., Wand A.J., Penning T.M. Using Biochemistry and Biophysics to Extinguish Androgen Receptor Signaling in Prostate Cancer. Invited Review. **J Biol Chem.** Dec. 2020 (accepted)

2. Deng Q., Rasool R.U., Russell R., Natesan R., **Asangani I.A.** Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. **bioRxiv.** Oct 16, 2020. (corresponding author)

3. Chen J., Harding S.M., Natesan R., Tian L., Benci J.L., Li W., Minn A.J., **Asangani I.A.,** Greenberg R.A. Cell cycle checkpoints cooperate to suppress DNA and RNA associated molecular pattern recognition and anti-tumor immune responses. **Cell Reports.** August 13, 2020.

4. Zhao S.G., Chen W.S., Li H., Foye A. Zhang M., Sjöström M., Aggarwal R., Playdle D., Liao A., Alumkal J.J., Das R., Chou J., Hua J.T., Barnard T.J., Bailey A.M., Chow E.D., Perry M.D., Dang H.X., Yang R., Moussavi-Baygi R., Zhang L., Alshalalfa M., Laura Chang S., Houlahan K.E., Shiah Y.J., Beer T.M., Thomas G., Chi K.N., Gleave M., Zoubeidi A., Reiter R.E., Rettig M.B., Witte O., Yvonne Kim M., Fong L., Spratt D.E., Morgan T.M., Bose R., Huang F.W., Li H., Chesner L., Shenoy T., Goodarzi H., **Asangani I.A.,** Sandhu S., Lang J.M., Mahajan N.P., Lara P.N., Evans C.P., Febbo P., Batzoglou S., Knudsen K.E., He H.H., Huang J., Zwart W., Costello J.F., Luo J., Tomlins S.A., Wyatt A.W., Dehm S.M., Ashworth A., Gilbert L.A., Boutros P.C., Farh K., Chinnaiyan A.M., Maher C.A., Small E.J., Quigley D.A., Feng F.Y. The DNA methylation landscape of advanced prostate cancer. **Nature Genet.** 2020 Jul 13. doi: 10.1038/s41588-020-0648-8. Online ahead of print.

5. Yuan S., Natesan R., Sanchez-Rivers F.J., Li J., Bhanu N.V., Yamazoe T., Lin J.H., Merrell A.J., Sela Y., Thomas S.K., Jiang Y., Plesset J.B., Miller E.M., Shi J., Garcia B.A., Lowe S.W., **Asangani I.A.,** Stanger B.Z. Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression. **Cancer Discovery.** 2020 Jun;10(6):854-871. doi: 10.1158/2159-8290.CD-19-1299. Epub 2020 Mar 18.

6. Devalaraja S., Jerrick T.T.K., Folkert I.W., Natesan R., Alam A.Z., Li M., Tada Y., Budagyan K., Dang M., Zhai L., Lobel G.P., Ciotti G.E., Eisinger-Mathason T.S.K., **Asangani I.A.,** Weber K., Simon C., Haldar M. Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression and resistance to immune checkpoint blockade. **Cell**. 2020. Mar 19;180(6):1098-1114.e16. doi: 10.1016/j.cell.2020.02.042. Epub 2020 Mar 12.

7. Natesan R., Aras S., Sander Effron S., **Asangani I.A.** Epigenetic regulation of chromatin in prostate cancer. **Adv Exp Med Biol.** Dec. 2019;1210:379-407. Book Chapter. (corresponding author)

8. Rasool R.U., Natesan R., Deng Q., Aras S., Lal P., Sander Effron S., Mitchell-Velasquez E., Posimo J.M., Carskadon S., Baca S.C., Pomerantz M.M., Siddiqui J., Schwartz L.E., Lee D.J., Palanisamy N., Narla G., Den R.B., Freedman M.L., Brady D.C., **Asangani I.A.** CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation. **Cancer Discovery** Aug 2019 Notes: doi: 10.1158/2159-8290 CD-19-0189. (corresponding author). *Featured in Cancer Discovery* and *Science Translational Medicine, Daily Mirror (UK).*

9. Kregel S., Malik R., **Asangani I.A.,** Wilder-Romans K., Rajendiran T., Xiao L., Vo J.N., Soni T., Cieslik M., Fernadez-Salas E., Zhou B., Cao X., Speers C., Wang S., Chinnaiyan A.M. Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. **Clin Cancer Res.** 25(13): 4038-4048, Jul 1 2019 Notes: doi: 10.1158/1078-0432.CCR-18-3776. Epub 2019 Mar 27.

10. Siddiqui A., Gollavilli P.N., Schwab A., Vazakidou M.E., Ersan P.G., Ramakrishnan M., Pluim D., Coggins S., Saatci O., Annaratone L., Hm Schellens J., Kim B., **Asangani I.A.,** Rasheed S.A.K., Marchiò C., Sahin O., Ceppi P. Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. **Cell Death Differ** Feb 2019 Notes: doi: 10.1038/s41418-019-0289-6.

11. Gollavilli P.N., Pawar A., Wang S., Wilder-Romans K., Ramakrishnan N., Engelke C.G., Dommeti V.L., Krishnamurthy P.M., Nallasivam A., Apel I.J., Xu T., Qin Z.S., Feng F.Y., **Asangani I.A.** EWS/ETS-driven Ewing Sarcoma requires BET bromodomain proteins. **Cancer Res**. June 13, 2018. (corresponding author)

12. Pawar A., Gollavilli P.N, Wang S., **Asangani I.A.** Resistance to BET inhibitor leads to alternative therapeutic vulnerabilities in castration-resistant prostate cancer. **Cell Reports**. Feb. 27, 2018. (corresponding author)

13. Stypulkowski E., **Asangani I.A.,** Witze E. APT1 directs the asymmetric partitioning of Notch and Wnt signaling during cell division. **Sci. Signaling.** Jan. 02, 2018.

14. Chakravarthi B.V.S.K., Chandrashekar D.S, Agarwal S., Balasubramanya S.A.H., Pathi S.S., Goswami M.T., Jing X., Wang R., Mehra R., **Asangani I.A.,** Chinnaiyan A.M., Manne U., Sonpavde G., Netto G.J., Gordetsky J., Varambally S. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. **Mol Cancer Res**. 2017 Oct 12.

15. Wang X., Qiao Y., **Asangani I.A.,** Ateeq B., Poliakov A., Cieślik M., Pitchiaya S., Chakravarthi B.V.S.K., Cao X., Jing X., Wang C.X., Apel I.J., Wang R., Tien J.C., Juckette K.M., Yan W., Jiang H., Wang S., Varambally S., Chinnaiyan A.M. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. **Cancer Cell.** 2017 Jun 12;31(6):844-847. doi: 10.1016/j.ccell.2017.05.001.

16. **Asangani I.A.,** Wilder-Romans K., Dommeti V.L., Krishnamurthy P.M., Apel I.J., Escara-Wilke J., Plymate S.R., Navone N.M., Wang S., Feng F.Y., Chinnaiyan A.M. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. **Mol Cancer Res**. 2016 Jan 20. Highly cited paper of MCR for the year 2016-18.

Before 2016 (Graduate and postdoc work)

17. Mody R.J., Wu Y.M., Lonigro R.J., Cao X., Roychowdhury S., Vats P., Frank K.M., Prensner J.R., **Asangani I.,** Palanisamy N., Dillman J.R., Rabah R.M., Kunju L.P., Everett J., Raymond V.M., Ning Y., Su F., Wang R., Stoffel E.M., Innis J.W., Roberts S.J., Robertson P.L., Yanik G., Chamdin A., Connelly J.A., Choi S., Harris C.A., Kitko C., Rao R.J., Levine J.E., Castle V.P., Hutchinson R.J., Talpaz M., Robinson D.R., Chinnaiyan A.M. Use of Integrative Clinical Sequencing in the Management of Pediatric Cancer Patients. **JAMA**. Sept. 2015.

18. Scanlon C.S., Banerjee R., Inglehart R.C., Liu M., Russo N., Hariharan A., van Tubergen E.A., Corson S.L., **Asangani I.A.,** Mistretta C.M., Chinnaiyan A.M., D'Silva N.J. Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. **Nature Commun**. 2015 Apr 28;6:6885. doi: 10.1038/ncomms7885.

19. Malik R., Khan A.P., **Asangani I.A.,** Cieslik M., Prensner J.R., Wang X., Iyer M.K., Xia Jiang1,2, Borkin D., Escara-Wilke J., Wu Y.M., Niknafs Y.S, Jing X., Qiao Y., Palanisamy N., Kunju L.P., Krishnamurthy P.M., Mellacheruvu D., Nesvizhskii A.I., Cao X., Dhanasekaran S.M., Feng F.Y., Grembecka J., Cierpicki T., Chinnaiyan A.M. Targeting the MLL complex in castration resistant prostate cancer. **Nature Med.** 2015 Mar 30. doi: 10.1038/nm.3830.

20. Chinni S., Powell K., Louie S., Conley-LaComb M.K., **Asangani I.,** Ginsburg K.B., Yi-Mi W., Williams J.L., Squire J.A., Maddipati K., Cher M.L. ERG/AKR1C3/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells. **Clin Cancer Res.** 2015 Mar 9. pii: clincanres.2352.2014.

21. Malik R, Patel L, Prensner J.R, Shi Y, Iyer M, Subramaniyan S, Carley A, Niknafs Y.S, Sahu A, Han S, Ma T, Liu M, **Asangani I.A**, Jing X, Cao X, Dhanasekaran SM, Robinson D, Feng F.Y, Chinnaiyan A.M. The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer. **Mol Cancer Res**. 2014 Jul 16. pii: molcanres.0257.2014..

22. Alluri P.G, **Asangani I.A**, Chinnaiyan A.M. BETs abet Tam-R in ER-positive breast cancer. **Cell Res**. 2014 Jul 8. doi: 10.1038/cr.2014.90. [Epub ahead of print].

23. **Asangani I.A** and Chinnaiyan A.M. BETting on a New Prostate Cancer Treatment. **Cell Cycle.** 2014 Jul 1;13(13):2015-6. doi: 10.4161/cc.29459. Epub 2014 Jun 6.

24. **Asangani I.A**., Dommeti L, Wang X , Rendong Y, Malik R, Wilder-Romans K, Dhanireddy S, Iyer M.K., Wu Y.M., Cao X., Qin Z.S., Wang S., Feng F.Y., Chinnaiyan A.M. Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer. **Nature**. 2014 Apr 23. *Featured in Nature Reviews Cancer, Nature Reviews Urology, Cancer Discovery and Asian Journal of Andrology.*

25. Prensner J.R., Sahu A., Iyer M.K., Malik R., Chandler B., **Asangani I.A.**, Poliakov A., Vergara I.A., Alshalalfa M., Jenkins R.B., Davicioni E., Feng F.Y., Chinnaiyan A.M. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. **Oncotarget.** 2014 Mar 23.

26. Prensner J.R., Iyer M.K., Sahu A., **Asangani I.A**., Cao Q., Patel L., Vergara I.A., Davicioni E., Erho N., Ghadessi M., Jenkins R.B., Triche T.J., Malik R., Bedenis R., McGregor N., Chen W., Han S., Jing X., Cao X., Wang X., Chandler B., Yan W., Siddiqui J., Kunju L.P., Dhanasekaran S.M., Pienta

K.J., Feng F.Y., Chinnaiyan A.M. The lncRNA SChLAP1 coordinates aggressive prostate cancer and antagonizes the SWI/SNF complex. **Nature Genet**. Sep 29. 2013. (Second author).

27. Khan A.P., Thekkelnaycke R.M., Ateeq B., **Asangani I.A.**, Athanikar J.N., Yocum A.K., Mehra R., Siddiqui J., Palapattu G., Wei J.T., Michailidis G., Sreekumar A., Chinnaiyan AM. The Role of Sarcosine Metabolism in Prostate Cancer Progression. **Neoplasia.** 2013 May;15(5):491-501.

28. **Asangani I.A.**, Ateeq B., Cao Q., Dodson L., Pandhi M., Kunju L.P., Mehra R., Lonigro R.J., Siddiqui J., Palanisamy N., Wu Y.M., Cao X., Kim J.H., Zhao M., Qin Z.S., Iyer M.K., Maher C.A., Kumar-Sinha C., Varambally S., Chinnaiyan AM. Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. **Molecular Cell**. 2012 Nov 13.

29. Wang R., **Asangani I.A.**, Chakravarthi B.V.S.K., Ateeq B., Lonigro R.J., Cao Q., Mani R.S., Camacho D., McGregor N., Jing X., Menawat R., Tomlins S.A., Zheng H., Otte A.P., Siddiqui J., Mehra R., Palanisamy N., Dhanasekaran S.M., Kunju L.P., Nyati M.K., Pienta K.J., Rubin M.A., Chinnaiyan A.M.,Varambally S. Role of Transcriptional Co-Repressor CtBP1 in Prostate Cancer Progression. **Neoplasia**. 2012 Oct;14(10):905-14.

30. **Asangani I.A.**, Harms P.W., Dodson L., Pandhi M., Kunju L.P., Maher C.A., Fullen D.R., Johnson T.M., Giordano T.J., Palanisamy N., Chinnaiyan A.M. Genetic and epigenetic loss of microRNA31 leads to feed-forward expression of EZH2 in melanoma. **Oncotarget.** 2012 Aug 31.

31. Kalyana-Sundaram S., Kumar-Sinha C., Shankar S., Robinson D.R., Wu Y.M., Cao X., **Asangani I.A.**, Kothari V., Prensner J.R., Lonigro R.J., Iyer M.K., Barrette T., Shanmugam A., Dhanasekaran S.M., Palanisamy N., Chinnaiyan A.M. Expressed pseudogenes in the transcriptional landscape of human cancers. **Cell.** 2012 Jun 22; 149(7):1622-34.

32. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., **Asangani I.A.**, Ateeq B., Chun S.Y., Siddiqui J., Sam L., Anstett M., Mehra R., Prensner J.R., Palanisamy N., Ryslik G.A., Vandin F., Raphael B.J., Kunju L.P., Rhodes D.R., Pienta K.J., Chinnaiyan A.M., Tomlins S.A. The mutational landscape of lethal castration-resistant prostate cancer. **Nature**. 2012 Jul 12;487(7406):239-43..

33. Robinson D.R., Kalyana-Sundaram S., Wu Y.M., Shankar S., Cao X., Ateeq B., **Asangani I.A.**, Iyer M., Maher C.A., Grasso C.S., Lonigro R.J., Quist M., Siddiqui J., Mehra R., Jing X., Giordano T.J., Sabel M.S., Kleer C.G., Palanisamy N., Natrajan R., Lambros M.B., Reis-Filho J.S., KumarSinha C., Chinnaiyan A.M. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. **Nature Med**. 2011 Nov 20;17(12):1646-51.

34. Leupold J.H., **Asangani I.A.**, Mudduluru G., Allgayer H. Promoter cloning and characterization of the human programmed cell death protein 4 (pdcd4) gene: evidence for ZBP-89 and Sp-binding motifs as essential Pdcd4-regulators. **Biosci Rep**. 2011 Nov 23.

35. Cao Q., Mani R.S., Ateeq B., Dhanasekaran S.M., **Asangani I.A.**, Prensner J.R., Kim J.H., Brenner J.C., Jing X., Cao X., Wang R., Li Y., Dahiya A., Wang L., Pandhi M., Lonigro R.J., Wu Y.M., Tomlins S.A., Palanisamy N., Qin Z., Yu J., Maher C.A., Varambally S., Chinnaiyan A.M. Coordinated regulation of polycomb group complexes through microRNAs in cancer. **Cancer Cell**. 2011 Aug 16;20(2):187-99.

36. Prensner J.R., Iyer M.K., Balbin O.A., Dhanasekaran S.M., Cao Q., Brenner J.C., Laxman B., **Asangani I.A.**, Grasso C.S., Kominsky H.D., Cao X., Jing X., Wang X., Siddiqui J., Wei J.T., Robinson D., Iyer H.K., Palanisamy N., Maher C.A., Chinnaiyan A.M. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. **Nature Biotechnol**. 2011 Jul 31;29(8):742-9.

37. Wang X.S., Shankar S., Dhanasekaran S.M., Ateeq B., Sasaki A.T., Jing X., Robinson D., Cao Q., Prensner J.R., Yocum A.K., Wang R., Fries D.F., Han B., **Asangani I.A.**, Cao X., Li Y., Omenn G.S., Pflueger D., Gopalan A., Reuter V.E., Kahoud E.R., Cantley L.C., Rubin M.A., Palanisamy N., Varambally S., Chinnaiyan A.M. Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. **Cancer Discov**. 2011 Jun 1; 1(1):35-43.

38. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., **Asangani I.A.**, Patel S., Wang X., Liang H., Yu J., Palanisamy N., Siddiqui J., Yan W., Cao X., Mehra R., Sabolch A., Basrur V., Lonigro R.J., Yang J., Tomlins S.A., Maher C.A., Elenitoba-Johnson K.S., Hussain M., Navone N.M., Pienta K.J., Varambally S., Feng F.Y., Chinnaiyan A.M. Mechanistic rationale for inhibition of poly(ADPribose) polymerase in ETS gene fusion-positive prostate cancer. **Cancer Cell**. 2011 May 17;19(5):664-78.

39. Ateeq B., Tomlins S.A., Laxman B., **Asangani I.A.**, Cao Q., Cao X., Li Y., Wang X., Feng F.Y., Pienta K.J., Varambally S., Chinnaiyan A.M. Therapeutic targeting of SPINK1-positive prostate cancer. **Sci Transl Med**. 2011 Mar 2; 3(72):72ra17.

40. Mudduluru G., George-William J.N., Muppala S., **Asangani I.A.**, Kumarswamy R., Nelson L.D., Allgayer H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. **Biosci Rep**. 2011 Jun; 31(3):185-97.

41. Rasheed S.A., Efferth T., **Asangani I.A.**, Allgayer H. First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. **Int J Cancer**. 2010 Sep 1; 127(6):1475-85.

42. Nikolova D.A., **Asangani I.A.**, Nelson L.D., Hughes D.P., Siwak D.R., Mills G.B., Harms A., Buchholz E., Pilz L.R., Manegold C., Allgayer H. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. **Cancer Res**. 2009 Mar 15;69(6):2461-70. Epub 2009 Mar 10.

43. **Asangani I.A.**, Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. **Oncogene**. 2008 Apr 3;27(15): 2128-36. Epub 2007 Oct 29.“Featured article”. Times Cited: 2050. Note. This paper was among the 50 highly cited cancer papers for the year 2008-2010, reported in the journal Nature Medicine.

44. Limaye A.M., **Asangani I.**, Kalyani T., Kondaiah P. Changes in gene expression following androgen receptor blockade is not equivalent to androgen ablation by castration in the rat ventral prostate. **J Biosci.** 2008 Jun; 33(2): 209-20.

45. **Asangani I.A.**, Rasheed S.A., Leupold J.H., Post S., Allgayer H. NRF-1, and AP-1 regulate the promoter of the human calpain small subunit 1 (CAPNS1) gene. **Gene**. 2008 Feb 29;410(1): 197206. Epub 2007 Dec 23.

46. Limaye A.M., **Asangani I.,** Bora N., Kondaiah P. Novel flutamide regulated genes in the rat ventral prostate: differential modulation of their expression by castration and flutamide treatments. **Asian J Androl.** 2007 Nov;9(6): 801-8.

47. Leupold J.H., Yang H.S., Colburn N.H., **Asangani I.**, Post S., Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. **Oncogene.** 2007 Jul 5;26(31): 4550-62. Epub 2007 Feb 12.

48. Leupold J.H., **Asangani I.**, Maurer G.D., Lengyel E., Post S., Allgayer H. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. **Mol Cancer Res**. 2007 May;5(5): 485-96.

49. Wang H., Yan C., **Asangani I.**, Allgayer H., Boyd D.D. Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. **Oncogene**. 2007 Mar 29;26(14): 2058-70. Epub 2006 Sep 25.

50. Schewe D.M., Biller T., Maurer G., **Asangani I.A.**, Leupold J.H., Lengyel E.R., Post S., Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. **Clin Cancer Res**. 2005 Dec 15;11(24 Pt 1): 8538-48.

EDITORIAL RESPONSIBILITIES

Adhoc reviewer for Cancer Discovery, Science Advances, Nature Communications, Nature Drug Discovery, Elife, European Urology, Cell Reports, Epigenetics & Chromatin, Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Journal of Experimental Medicine, Molecular Oncology, BMC, Oncogene, Oncotarget, Neoplasia, International Journal of Cancer, PLOS One, Cancer, Prostate.

Guest Editor: BioMed Research International.

CONSULTING

2014- 2015	Oncofusion Therapeutics Inc. Ann Arbor. Michigan.
2017- 2019	Zenith Epigenetics, San Francisco. California

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIP

2018- Present	Scientific Reviewer, DOD/CDMRP
2013- Present	Scientific Reviewer, Prostate Cancer Foundation (PCF)
2020- Present	Scientific Reviewer, Swiss National Science Foundation (SNSF)
2010- Present	Member, American Association of Cancer Research (AACR)
2020- Present	Member, Society for Basic Urologic Research (SBUR)

MAJOR INVITED PROFESSORSHIPS AND LECTURESHIPS

(2016-Present)

1. Eppley Institute Seminar Series, University of Nebraska, October 8th, 2020
2. American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020.
3. Epigenetics Monthly Seminar Series, Penn Epigenetics Institute, University of Pennsylvania, Philadelphia, October 3, 2019.

4. Basser Center for BRCA monthly conference, University of Pennsylvania, Philadelphia, September 6, 2019
5. Prostate Cancer Working Group, Sidney Kimmel Cancer Centers at Thomas Jefferson University, Philadelphia, May 23, 2018.
6. 4th Annual Sidney Kimmel Cancer Centers' Prostate Cancer Amtrak Alliance Summit. Thomas Jefferson University, Philadelphia, June 29, 2017.
7. Cambridge Healthtech Institute, Discovery on Target- Boston, September 2016.
8. The 7th Biennial Great Lakes Nuclear Receptor Conference (GLNRC). Case Western Reserve University, Cleveland, OH. October 2016.
9. Third Annual Symposium, Wake Forest University, Winston-Salem, NC. April 15-16, 2016.

(2013-2015)

1. 8th Annual Prostate Cancer Program Retreat. Fort Lauderdale, Florida. March 2015. 2.
21st Prostate Cancer Foundation Retreat. Carlsbad, San Diego. October 2014
3. Cambridge Healthtech Institute, Discovery on Target- Boston October 2014.
4. Medivation Inc. San Francisco. May 2014.
5. 7th Annual Prostate Cancer Program Retreat. Fort Lauderdale, Florida. March 2014.
6. Cambridge Healthtech Institute Discovery on Target- Boston September 2013.

ACADEMIC AND INSTITUTIONAL COMMITTEES

2012-2015	Member, Michigan Center for Translational Pathology faculty search committee
2012-2015	Participating Member, Precision Medicine Sequencing Tumor Board, MI-Oncoseq, Michigan Center for Translational Pathology
2013-Present	Member, Prostate Cancer Foundation research award review committee
2013-Present	Prostate Cancer Foundation research award standing review committee member
2017-Present	Cell and Molecular Biology Program Admissions
2017-Present	Cancer Biology Student Advising Committee
2017-Present	Abramson Family Cancer Research Institute Seminar Committee
2020-Present	Member, Cancer Biology Graduate Recruitment Program CAMB,
2017-2020	Thesis committee for Salina Yuan, MD-PhD, Cell and Molecular Biology - Cancer Biology, University of Pennsylvania
2017-2020	Thesis Committee Mentor for Michael Werner, Department of Immunology, University of Pennsylvania.
2017-Present	Thesis committee for Qiaosi Tang, Cell and Molecular Biology - Cancer Biology, University of Pennsylvania.
2017-2020	Thesis committee for Dylan Marchione, Department of Pharmacology, University of Pennsylvania.
2018-Present	Thesis Committee for Grant Grothusen, Cell and Molecular Biology - Cancer Biology, University of Pennsylvania
2018-Present	Thesis Committee for Yekaterina Kori, Biochemistry and Molecular Biophysics Graduate Group, University of Pennsylvania.
2018-Present	Thesis Committee for Jonuelle Acosta, Cell and Molecular Biology - Cancer Biology, University of Pennsylvania.
2019-Present	Thesis Committee for Zvi Crammer, Cell and Molecular Biology - Cancer Biology, University of Pennsylvania.

MAJOR ACADEMIC AND TEACHING RESPONSIBILITIES

2020-Present	Graduate Student Mentor for Erick Mitchell, Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, PA.
2020-Present	Postdoctoral Fellow Mentor for Chandan Kanta Das, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA.
2018-Present	Postdoctoral Fellow Mentor for Shweta Aras, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA.
2020-Present	Mentor for Mohammed Alhusayan (Internship, M.S. Candidate, Biomedical Engineering, Drexel University, Philadelphia.
2018-Present	Postdoctoral Fellow Mentor for Reyaz ur Rasool, Department of Cancer Biology, University of Pennsylvania
2017-Present	Postdoctoral Fellow Mentor for Qu Deng, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA.
2020-2020	MSTP Graduate Program Independent Study Mentor to Napasorn (Nina) Kuprasertkul, University of Pennsylvania, Philadelphia, PA.
2018-2020	Research Fellow Mentor for Ramakrishnan Natesan, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA.
2018-2019	Graduate Student Mentor for Sam Sander Effron, Cancer Biology Graduate Group, University of Pennsylvania, Philadelphia, PA.
2017-2019	Faculty Course Co-Director CAMB 530: The cell cycle, genome integrity and cancer, University of Pennsylvania, Philadelphia, PA.
2018	Graduate Student Rotation Mentor for Natalie Toothacre, Cell and Molecular Biology Graduate Group, University of Pennsylvania
2017	Sidhant Nair, Downingtown STEM Academy - IB World School, Downingtown, PA
2017-2018	High School Student Mentor for Shebeel Arif, Central High School, Philadelphia, PA,
2017-2018	Graduate Student Mentor for Aryel Heller, Cell and Molecular Biology Graduate Group, University of Pennsylvania
2017	Undergraduate Student Mentor for Ashish Dahal, University of Pennsylvania, Philadelphia, PA
2016-2017	Undergraduate Student Mentor for Yasmina al Ghadban, School of Engineering and Science, University of Pennsylvania, Philadelphia, PA
2017	Graduate Student Rotation Mentor for Zvi Cramer, Cell and Molecular Biology Graduate Group, University of Pennsylvania. Philadelphia, PA.
2016-2017	Graduate Student Rotation Mentor for Osvaldo Rivera, Cell and Molecular Biology Graduate Group, University of Pennsylvania
2016-2017	Postdoctoral Fellow Mentor for Paradesi Gollavilli, Department of Cancer Biology, University of Pennsylvania
2016	Faculty Course Co-Director CAMB 512: Cancer Biology and Genetics, University of Pennsylvania
2017	Undergraduate Student Mentor for Alyson Marshall, Cabrini University, PA
2016	High School Student Mentor for Nora-Lovette Okwara, Neshaminy High School, Neshaminy, PA
2016	Undergraduate Student Mentor for Akash Halagur, Center for Neuroscience & Society, University of Pennsylvania, Philadelphia, PA.